Cepheid
Total Raised
$58.45MInvestors Count
13Deal Terms
2Funding, Valuation & Revenue
7 Fundings
Cepheid has raised $58.45M over 7 rounds.
Cepheid's latest funding round was a Grant for $28M on July 30, 2021.
Cepheid's valuation in November 2016 was $4,000M.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
7/30/2021 | Grant | $28M | 1 | |||
11/5/2016 | Acq - P2P | $4,000M | ||||
6/21/2000 | IPO | |||||
1/6/2000 | Series C | |||||
4/13/1998 | Series B |
Date | 7/30/2021 | 11/5/2016 | 6/21/2000 | 1/6/2000 | 4/13/1998 |
|---|---|---|---|---|---|
Round | Grant | Acq - P2P | IPO | Series C | Series B |
Amount | $28M | ||||
Investors | |||||
Valuation | $4,000M | ||||
Revenue | |||||
Sources | 1 |
Cepheid Deal Terms
2 Deal Terms
Cepheid's deal structure is available for 2 funding rounds, including their Acq - P2P from November 05, 2016.
Round | Acq - P2P | Series B |
|---|---|---|
Funding Date | ||
Pre-Money Valuation | ||
Post-Money Valuation | ||
Amount Raised | ||
Shares Authorized | ||
Issuance Price | ||
Dividend Rate | ||
Liquidation Preferences | ||
Liquidation Price | ||
Participation | ||
Conversion Price | ||
Anti Dilution | ||
General Voting | ||
Board Voting | ||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acq - P2P | |||||||||||||||
Series B |
Cepheid Investors
13 Investors
Cepheid has 13 investors. US Department of Health and Human Services invested in Cepheid's Grant funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
7/30/2021 | 7/30/2021 | 1 Grant | Government | DC | ||
11/5/2016 | 11/5/2016 | 1 Acq - P2P | Corporation | DC | ||
4/13/1998 | 1/6/2000 | 2 Series B, Series C (2000) | Investment Bank | New York | ||
Corporation | Minnesota | |||||
Private Equity | New York |
First funding | 7/30/2021 | 11/5/2016 | 4/13/1998 | ||
|---|---|---|---|---|---|
Last Funding | 7/30/2021 | 11/5/2016 | 1/6/2000 | ||
Investor | |||||
Rounds | 1 Grant | 1 Acq - P2P | 2 Series B, Series C (2000) | ||
Board Seats | |||||
Type | Government | Corporation | Investment Bank | Corporation | Private Equity |
Location | DC | DC | New York | Minnesota | New York |
Cepheid Acquisitions
2 Acquisitions
Cepheid acquired 2 companies. Their latest acquisition was OncoMark on December 16, 2021.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
12/16/2021 | Other | $9.9M | Acquired | 4 | ||
10/3/2014 |
Date | 12/16/2021 | 10/3/2014 |
|---|---|---|
Investment Stage | Other | |
Companies | ||
Valuation | ||
Total Funding | $9.9M | |
Note | Acquired | |
Sources | 4 |
Compare Cepheid to Competitors
Mimark focuses on the development of diagnostic solutions for gynecological diseases within the healthcare sector. The company provides a diagnostic approach that utilizes gynecological fluids to assist in the diagnosis of gynecological conditions. Their main products include GyLDEC for endometrial cancer diagnosis and GyLDENDO for endometriosis diagnosis, both of which are based on protein biomarker analysis and designed to be less invasive. It was founded in 2021 and is based in Barcelona, Spain.
Thermo Fisher Scientific serves the science sector with a range of products and services. The company offers scientific research tools, biotechnology products, and diagnostic testing equipment, as well as laboratory and pharmaceutical development services. Thermo Fisher Scientific serves the biotech, biopharma, contract development and manufacturing organization (CDMO), lab diagnostics, and industrial and applied sciences sectors. Thermo Fisher Scientific was formerly known as Thermo Electron. It was founded in 2006 and is based in Waltham, Massachusetts.
RLDatix focuses on healthcare through governance, risk, and compliance tools. It offers a suite of cloud-based software designed to help with healthcare-acquired infections and facilitate reporting on adverse events. It primarily serves the healthcare industry, providing solutions to healthcare organizations. RLDatix was formerly known as Datix Business Systems. It was founded in 1986 and is based in Chicago, Illinois.
Biomeme focuses on DNA diagnostics and disease surveillance in healthcare and research. The company provides a platform that allows smartphones to analyze and identify pathogens and diseases based on their DNA or RNA signatures. Biomeme serves the healthcare, agriculture, environmental, veterinary, and educational sectors with mobile testing solutions. It was founded in 2012 and is based in Philadelphia, Pennsylvania.
Hologic operates as a medical technology company focused on women's health through its diagnostic, surgical, and medical imaging products. The company provides services for the detection, diagnosis, and treatment of health conditions related to female health. Hologic's products are utilized across various sectors in the medical field. It was founded in 1985 and is based in Marlborough, Massachusetts.
binx health focuses on point-of-care molecular diagnostics within the healthcare sector. The company offers diagnostic solutions that provide testing solutions for sexually transmitted infections such as chlamydia and gonorrhea. binx health was formerly known as Atlas Genetics. It was founded in 2005 and is based in Cambridge, Massachusetts.
Loading...